-
Mashup Score: 2Experts Forecast Cancer Research and Treatment Advances in 2023 - 1 year(s) ago
Experts in several leading fields of cancer research discussed potential new advances against cancer in the coming year.
Categories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 0mRNA Cancer Vaccine Shows Promise in Early Trial - 1 year(s) ago
Melanoma patients who had vax plus PD-1 inhibitor did better than those on pembrolizumab alone
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
An investigational mRNA #cancervaccine met its primary endpoint in a phase IIb study, @moderna_tx and @Merck announced Tuesday. Moderna CEO Stéphane Bancel called the results "highly encouraging for the field of cancer treatment." https://t.co/FE36mwhZ7h @KristinaMFiore
-
-
Mashup Score: 0
The company said that in a phase 2 clinical trial, the vaccine, when combined with immunotherapy drug Keytruda, reduced the risk of recurrence by 44%.
Source: NBC NewsCategories: Latest Headlines, Oncologists2Tweet-
Promising, albeit hyped, preliminary data from Moderna, the company that produces mRNA vaccines, for a personalized #CancerVaccine against advanced melanoma, @AP https://t.co/5GCX7yrPuX via @nbcnews
-
-
Mashup Score: 3Cancer mRNA vaccine completes pivotal trial - 1 year(s) ago
It uses the same messenger-RNA technology as some Covid-19 vaccines.
Source: BBC NewsCategories: Healthcare Professionals, Latest HeadlinesTweet-
Another good news today! A pivotal trial of a personalized #cancervaccine that uses the same messenger-RNA technology as COVID jabs was just completed! @moderna_tx and @Merck are behind it, and they called the results "a new paradigm" moment. https://t.co/Vv6JALD3vj
-
-
Mashup Score: 1
BioNTech presented promising early stage data about its cancer vaccine candidate BNT211 during the recent European Society for Medical Oncology (ESMO) Congress 2022, but the results didn’t lift the company’s stock.
Categories: Future of Medicine, Latest HeadlinesTweet-
StockWatch: BioNTech Sees No Bounce from Promising Cancer Vaccine Data BioNTech presented promising early stage data about its #cancervaccine candidate BNT211 during #ESMO Congress 2022, but the results didn’t lift the company’s stock. Learn more: https://t.co/9FX3ZPlBay #stocks https://t.co/Vjn2vpeR3B
-
-
Mashup Score: 17New cancer vaccine delivers double punch to tumors - 2 year(s) ago
Novel design stimulates a coordinated attack by T and natural killer cells that prevents metastasis in mice
Source: Wyss InstituteCategories: Healthcare Professionals, Latest HeadlinesTweet-
A new type of #CancerVaccine tested in mice greatly reduced metastasis & was active against tumor cells resistant to other immunotherapies. The vaccine works by taking away a defense strategy of the tumor and producing an immune cell attack. https://t.co/A8e6SIUAfs @theNCI #NIH
-
-
Mashup Score: 0
Immunotherapy has been a milestone in combatting cancer, by complementing or even replacing classic treatments like surgery, chemotherapy, radiation, and anti-hormonal therapy. In 15%-30% of breast cancers, overexpression of the human epidermal growth factor receptor 2 (Her-2/neu) is associated with more aggressive tumor development. Passive immunization/immunotherapy with the recombinantly…
Source: Esmo OpenCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Check out the newest @ESMO_Open review: Vaccination against Her-2/neu, with focus on peptide-based vaccines #cancervaccine @cczielinski @myESMO #OncoAlert https://t.co/9MpFKQ64zJ https://t.co/NhGMCfX7EZ
-
-
Mashup Score: 5The Sympathetic Nervous System Modulates Cancer Vaccine Activity through Monocyte-Derived Cells - 2 year(s) ago
This article is featured in Top Reads , p.[][1] [1]: /lookup/volpage/207/2899
Source: The Journal of ImmunologyCategories: Allergy-Immunology, Latest HeadlinesTweet-
#JI_TopRead from Dr. Haifa Shen @Nanomed_hmri and colleagues | The #SympatheticNervousSystem Modulates #CancerVaccine Activity Through Monocyte-Derived Cells https://t.co/RY5pYzslZI #ReadTheJI #immunology https://t.co/76xKPB4SVM
-
-
Mashup Score: 0Cancer Vaccine Development: ImmunoMedicine: Vol 1, No 1 - 3 year(s) ago
Click on the title to browse this issue
Source: Wiley Online LibraryCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Don't miss the first issue of ImmunoMedicine, a new #OpenAccess journal. Issue 1 is a special issue on #CancerVaccine Development. Read it now: https://t.co/YnAHWriaFE https://t.co/txSuHmlVeA
-
-
Mashup Score: 1Cancer Vaccine Development: ImmunoMedicine: Vol 1, No 1 - 3 year(s) ago
Click on the title to browse this issue
Source: Wiley Online LibraryCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Check out the first issue of ImmunoMedicine, a new #OpenAccess journal, available now! Issue 1 is a special issue on #CancerVaccine Development. Read it now: https://t.co/JaDQZPu5Bg https://t.co/UJRRNErvTW
-
Hot topics in immunotherapy in 2023! Great reading. It is full of hope for the future available therapies! #Immunotherapy #cancervaccine #combinedtherapies #solidtumors https://t.co/PgbCL3p7xL https://t.co/Rk0LubPTbQ